These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 22559147)

  • 1. Immune alterations and emerging immunotherapeutic approaches in lung cancer.
    Dasanu CA; Sethi N; Ahmed N
    Expert Opin Biol Ther; 2012 Jul; 12(7):923-37. PubMed ID: 22559147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines for the treatment of non-small cell lung cancer: investigational approaches and clinical experience.
    Mellstedt H; Vansteenkiste J; Thatcher N
    Lung Cancer; 2011 Jul; 73(1):11-7. PubMed ID: 21474197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches.
    Bockorny B; Dasanu CA
    Expert Opin Biol Ther; 2013 Jun; 13(6):911-25. PubMed ID: 23586712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immune alterations in lung cancer - the new therapeutic approach].
    Domagała-Kulawik J; Osińska I
    Pneumonol Alergol Pol; 2014; 82(3):286-99. PubMed ID: 24793154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy and lung cancer: current developments and novel targeted therapies.
    Domingues D; Turner A; Silva MD; Marques DS; Mellidez JC; Wannesson L; Mountzios G; de Mello RA
    Immunotherapy; 2014; 6(11):1221-35. PubMed ID: 25496336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing the immune system for the treatment of non-small-cell lung cancer.
    Brahmer JR
    J Clin Oncol; 2013 Mar; 31(8):1021-8. PubMed ID: 23401435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for lung cancer: ongoing clinical trials.
    Declerck S; Vansteenkiste J
    Future Oncol; 2014 Jan; 10(1):91-105. PubMed ID: 24143916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
    Rolfo C; Sortino G; Smits E; Passiglia F; Bronte G; Castiglia M; Russo A; Santos ES; Janssens A; Pauwels P; Raez L
    Expert Rev Anticancer Ther; 2014 Oct; 14(10):1173-87. PubMed ID: 25148289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Therapy.
    Lievense L; Aerts J; Hegmans J
    Adv Exp Med Biol; 2016; 893():59-90. PubMed ID: 26667339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current vaccine updates for lung cancer.
    Simmons O; Magee M; Nemunaitis J
    Expert Rev Vaccines; 2010 Mar; 9(3):323-35. PubMed ID: 20218860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel targeted agents for lung cancer.
    West HJ
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S41-6. PubMed ID: 19362946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Review on immunotherapies for lung cancer].
    Jin S; Tian J
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):606-11. PubMed ID: 23075686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belagenpumatucel-L for the treatment of non-small cell lung cancer.
    Rijavec E; Biello F; Genova C; Barletta G; Maggioni C; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Beltramini S; Grassi MA; Boccardo F; Grossi F
    Expert Opin Biol Ther; 2015; 15(9):1371-9. PubMed ID: 26211534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer developments in the immunotherapy of malignant melanoma.
    Maslin B; Alexandrescu DT; Ichim TE; Dasanu CA
    J Oncol Pharm Pract; 2014 Feb; 20(1):3-10. PubMed ID: 23435643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
    Perez CA; Santos ES; Raez LE
    Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.
    Shepherd FA; Douillard JY; Blumenschein GR
    J Thorac Oncol; 2011 Oct; 6(10):1763-73. PubMed ID: 21876456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune alterations in malignant melanoma and current immunotherapy concepts.
    Shimanovsky A; Jethava A; Dasanu CA
    Expert Opin Biol Ther; 2013 Oct; 13(10):1413-27. PubMed ID: 23930800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results.
    Vansteenkiste J; Zielinski M; Linder A; Dahabreh J; Gonzalez EE; Malinowski W; Lopez-Brea M; Vanakesa T; Jassem J; Kalofonos H; Perdeus J; Bonnet R; Basko J; Janilionis R; Passlick B; Treasure T; Gillet M; Lehmann FF; Brichard VG
    J Clin Oncol; 2013 Jul; 31(19):2396-403. PubMed ID: 23715567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.